抗内毒素治疗的新策略

脂多糖(Lipopolysaccharide,LPS)是G-菌造成的败血症或脓毒性休克病理中最重要的致病因素，若在整个病理过程的上游，即在细菌内毒素水平阻断脓毒性休克的发生，就可能限制或阻止病理性的次级炎症级联反应。本文综述了各种不同来源的LPS结合蛋白在结合LPS从而中和并阻断内毒素的过程中的功效及应用现状，探讨了最终用于人类败血症或脓毒性休克临床治疗的有效方案。

The New Antiendotoxin Strategies

Lipopolysaccharide(LPS)is important in the pathogenesis of sepsis infected by gram\|negative bacteria in humans,and part or all of this pathophysiology is mediated by a complex secondary inflammatory response.Administration of purified LPS or a variety of LPS\|free recombinant mediators can reproduce much of the pathophysiology of gram\|negative sepsis.There has been an explosion of new information over the last several years regarding the interactions of LPS with proteins and cells.Blocking sepsis at the bacterial toxin level is appealing because it is upstream,so that the secondary pathologic inflammatory cascade may be limited or prevented.A variety of antiendotoxin strategies have been proposed.Therapies under investigation include agents that bind and neutralize LPS,agents or systems that enhance LPS clearance,and agents that inhibit LPS interaction with serum elements or cellular receptors.